Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK-042 Phase III double-blind study in pediatric seasonal allergic rhinitis
jRCT2031240419Phase 3Active, not recruiting
- Sponsor
- Teikoku Seiyaku Co., Ltd.
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing Placebo 3 weeks with Placebo 1 week → TK-042 2 weeks (2 arms). Primary endpoint: Change from baseline in total nose symptom score. Started Feb 2025; status: active, not recruiting.
02
Drugs
donepezil
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on jRCT2031240419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240419.